Dedifferentiated Liposarcoma Clinical Trial
Official title:
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Trial of TQB3616 Capsules Versus Placebo in the Treatment of Dedifferentiated Liposarcoma
A clinical trial evaluating TQB3616 capsules versus placebo in the treatment of dedifferentiated liposarcoma. Divided into 2 stages, the second stage, a total of 118 subjects are planned to be enrolled.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03307616 -
Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery
|
Phase 2 | |
Completed |
NCT01913652 -
Ph II Cabazitaxel DD Liposarcoma
|
Phase 2 | |
Not yet recruiting |
NCT06389799 -
A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)
|
Phase 2 | |
Recruiting |
NCT05886634 -
A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma
|
Phase 2 | |
Completed |
NCT06115681 -
Real-world Study of Dedifferentiated Liposarcoma Patients in China
|
||
Active, not recruiting |
NCT02846987 -
Study of Abemaciclib in Dedifferentiated Liposarcoma
|
Phase 2 | |
Terminated |
NCT04979442 -
Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma
|
Phase 3 | |
Completed |
NCT02606461 -
Selinexor in Advanced Liposarcoma
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT04242238 -
Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas
|
Phase 1 | |
Withdrawn |
NCT00969917 -
Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma
|
Phase 2 | |
Active, not recruiting |
NCT03651375 -
Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall
|
Phase 2 | |
Terminated |
NCT03604783 -
Phase 1, First-in-human Study of Oral TP-1287 in Patients With Advanced Solid Tumors
|
Phase 1 |